Hims & Hers Health (HIMS) at $33.87 as of today represents either a massive opportunity or a value trap, depending on whether you believe the company can execute its extremely audacious vision.

I'm betting on execution - this is one of the longest holds in my all-stock portfolio and I recently added to my position at these levels.

HIMS is transforming from a niche telehealth provider focused on stigmatized conditions into a comprehensive healthcare platform that addresses dozens of conditions with personalized treatment plans. They're growing revenue at 49% annually while generating meaningful cash flow, and the path to their $6.5 billion revenue target by 2030 is becoming clearer each quarter.

First lets go over Q3 earnings numbers as we look forward to Q4 earnings in late February.

Revenue hit $599 million, up 49% year-over-year, while the subscriber base grew to 2.47 million. Thats a 21% increase. But the real story isn't just the growth rate, it's what's driving it.

Monthly revenue per subscriber jumped 19% to $80, which tells you customers aren't just sticking around, they're buying more. Subscribers using personalized treatment plans surged 50% year-over-year, and those trusting HIMS with multiple conditions increased 80%.

This is the platform flywheel starting to spin, and the economics only improve from here as they layer on higher-margin specialties.

The stock trades at a $7.4 billion market cap today after falling 54% from its February 2025 peak of $72.98.

That decline reflects legitimate concerns about GLP-1 competition and regulatory uncertainty, but in my opinion, the market is missing the bigger growth story. HIMS generated $78.4 million in adjusted EBITDA in Q3 2025 alone - a 13% margin on $599 million in revenue - and they're guiding to $2.335 to $2.355 billion for the full year 2025.

At a $7.4 billion valuation on approximately $2.35 billion in 2025 revenue, we're paying roughly 3.1x sales for a business growing at nearly 50% with positive cash flow and expanding margins.

For context, Teladoc trades at 1.5x sales but is growing at just 2-3% annually. The valuation makes sense if you think HIMS is mature, but completely misprices the business if they execute on the platform vision.

Let me start by explaining what HIMS actually does, because this isn't your typical telehealth story.

Most people think "HIMS = men's sexual health" or more recently "HIMS = GLP-1 weight loss drugs." Both are true but also incomplete. Think of HIMS as building the Amazon of personalized healthcare. HIMS wants to create a single platform where you can address sexual health, dermatology, mental health, weight management, hormone therapy, sleep issues, and eventually dozens of other conditions through a seamless digital experience backed by real doctors.

The business model is simple. Customers visit the HIMS or Hers website (Hers is the women-focused brand), complete a health intake assessment, get matched with a licensed healthcare provider who reviews their case, and if appropriate, receive a personalized treatment plan delivered to their door.

The whole process takes 24-48 hours and costs a fraction of traditional healthcare. More importantly, it's subscription-based - meaning that 95% of revenue is recurring with customer retention above 85%. This isn't one-time transactions, it's ongoing relationships where HIMS becomes your primary healthcare provider for an expanding set of conditions (and the platform is just scratching the surface).

HIMS currently offers treatments across multiple core specialties. This includes sexual health (the original category), dermatology (hair loss, acne, anti-aging skincare), mental health (anxiety, depression), and weight management (the explosive growth driver).

They reported $599 million in quarterly revenue with 2.47 million subscribers, which works out to roughly $80 per subscriber per month. But management disclosed that subscribers using personalized solutions - treatments customized to individual biology rather than one-size-fits-all prescriptions - grew 50% year-over-year. These personalized subscribers generate significantly higher revenue and retention because HIMS adjusts dosages, combines treatments, and refines protocols based on individual response.

The platform dynamic is real, not theoretical. The company shared that multi-condition subscribers, that’s people using HIMS for two or more health issues, increased 80% year-over-year in Q3 2025.

Think about yourself or someone you know as a customer. Someone starts with hair loss treatment, has a positive experience with the convenience and quality, then adds acne treatment, then starts using their mental health services. Each additional condition deepens the relationship, increases switching costs, and expands lifetime value.

This is exactly how Amazon worked - you started buying books, then added electronics, then groceries, until Amazon became your default.

I can't write about HIMS without addressing the biggest story that has taken up a lot of space in the headlines - GLP-1 weight loss treatments.

This category exploded from zero to a projected $725 million run rate in 2025 - roughly 31% of total company revenue. HIMS offers compounded versions of semaglutide (the active ingredient in Wegovy and Ozempic) and liraglutide, as well as oral weight loss options, at price points far below the branded alternatives. Compounded GLP-1 injections start at $199 per month on HIMS versus $1,000+ for branded Wegovy through traditional channels.

The regulatory situation is complex and has driven much of the stock volatility. The FDA removed semaglutide from the shortage list in early 2025, which technically means compounding pharmacies should stop producing it. HIMS pivoted to offering "personalized" compounded semaglutide - doses customized to individual patient needs, which may remain legal even without a shortage.

They're also in active discussions with Novo Nordisk to offer branded Wegovy and the upcoming oral Wegovy pill through their platform. Management mentioned these conversations multiple times on the Q3 earnings call, signaling a potential partnership that would legitimize their weight loss business while maintaining the affordability angle. I’m keeping a close eye on this story, as this would be a major catalyst, while failure to reach a deal could bring another wave of disappointment.

In all honesty, I'm not worried about GLP-1 regulatory risk.

HIMS released clinical data in July 2025 showing their holistic approach works. Customers taking compounded GLP-1s through HIMS lost an average of 20.9 pounds (10.3% of body weight) over six months, with only 10.3% reporting side effects. More importantly, 75% of HIMS customers remained on treatment after six months, compared to 80% dropout rates for commercial GLP-1s according to Blue Health Intelligence data (see the research report below).

That retention difference is massive and reflects HIMS's 24/7 care team access, nutritional support, and personalized dosing adjustments. They're not just selling medication, they're providing a comprehensive program that helps people succeed.

Even if compounded semaglutide faces additional restrictions, the weight loss business doesn't disappear. HIMS is launching liraglutide (Novo's older GLP-1 that recently came off patent), expanding oral options, and will have access to generic semaglutide in Canada starting in 2026 - potentially the first generic version globally. They acquired Canadian telehealth provider Livewell in December 2025 specifically to position for that launch.

The weight loss category is here to stay at scale, and HIMS has built the infrastructure and brand trust to capitalize regardless of which specific GLP-1 formulations are available.

The path from $2.4 billion in 2025 revenue to $6.5 billion by 2030 requires roughly 22% compound annual growth - aggressive but realistic if you understand what's being built. Management outlined five key priorities on their roadmap, and watching these unfold gives me confidence the target is achievable rather than aspirational.

First: Deepening personalization. HIMS currently offers hundreds of personalized treatment combinations, and they're building toward thousands. This means moving beyond "here's the standard dose of finasteride for hair loss" to "here's a customized protocol combining oral minoxidil at X dosage, topical finasteride at Y concentration, and biotin supplementation based on your lab results and response tracking."

The monthly revenue per subscriber metric is the key tracker here, growing 19% year-over-year to $80 in Q3 2025. Built into my assumption, I expect this to reach $100+ as personalization scales.

Second: Launching new specialties rapidly. HIMS entered weight management just 18 months before it became a $725 million annual business. They're applying the same playbook to menopause (launched Q4 2025), testosterone therapy (launched Q4 2025), and longevity medicine (planned for 2026). Each of these represents billion-dollar markets with massive unmet need.

The Hers brand specifically is on pace to generate $1 billion+ in revenue during 2026 according to CFO commentary, driven primarily by menopause and hormonal health - conditions that affect 50+ million women in the U.S. alone but remain dramatically underserved by traditional healthcare.

Third: International expansion. HIMS completed the acquisition of ZAVA, a European digital health platform, adding the UK, Germany, France, and Ireland to their footprint. They acquired Livewell for Canada. The UK weight loss program launched in November 2025, offering both GLP-1 options and comprehensive care at transparent pricing. CEO Andrew Dudum mentioned on the Q3 call that international represents a "foundation for a robust roadmap to one day reach tens of millions of users" globally.

If you assume HIMS can capture even 2-3% of adults in developed markets over the next decade, you're talking about 20-30 million potential subscribers.

Fourth: Diagnostic integration. In December 2025, HIMS announced the acquisition of YourBio Health, which developed pain-free blood sampling technology. This is strategic brilliance. Right now, if you want hormone testing or metabolic panels on HIMS, you still need to visit a lab. By integrating at-home diagnostics, they can close the loop entirely - initial consultation, at-home testing, personalized treatment, ongoing monitoring, all through one platform without leaving your house. This moves HIMS from convenient telehealth to comprehensive primary care replacement for many conditions.

Fifth: Strategic partnerships. Beyond the Novo Nordisk discussions, HIMS has partnered with Mount Sinai, Ochsner Health, and the American College of Cardiology. These relationships provide clinical credibility and potentially allow HIMS to offer more complex treatments that require institutional backing. Dudum specifically mentioned pursuing "investments, partnerships, and collaborations to build a single destination where customers can access a range of innovative offerings alongside the most personal, convenient care available."

One aspect of the HIMS model that's underappreciated is how the unit economics improve with scale rather than degrade. Marketing efficiency has strengthened dramatically - customer acquisition cost as a percentage of revenue dropped from 45% a year ago to 39% in Q3 2025. This happens because HIMS benefits from organic growth (existing customers adding conditions, word-of-mouth referrals) and because their brand awareness allows them to rely more on owned channels versus paid advertising.

Gross margins temporarily compressed from 79% to 74% in Q3 2025, but this is largely mix shift related to weight loss products, which have lower margins than dermatology or sexual health due to medication costs.

Management was explicit that they expect margins to normalize as the GLP-1 business shifts to refill cohorts (where margins improve) and as higher-margin specialties like menopause and testosterone scale.

The adjusted EBITDA margin of 13% in Q3 2025 is already solid for a high-growth healthcare business, and management's 2030 target of $1.3 billion EBITDA on $6.5 billion revenue implies 20% margins at scale which is certainly possible.

The cash generation is real and accelerating. Operating cash flow hit $149 million in Q3 2025, up 74% year-over-year, while free cash flow reached $79 million. The company ended Q3 with over $1.1 billion in cash and investments, including $630 million in cash and short-term investments. They announced a $250 million share repurchase program in November 2025, signaling confidence in the stock valuation and providing support during volatility.

For a business growing at nearly 50% while generating meaningful cash, the balance sheet is fortress-level strong.

Let me be clear about the risks, because they're substantial and the 54% stock decline reflects legitimate concerns.

The primary risk at the moment is regulatory.

If the FDA aggressively restricts compounded GLP-1s and HIMS can't secure partnerships with Novo Nordisk or Eli Lilly to offer branded versions, the weight loss business could shrink significantly. While management has mitigation strategies (liraglutide, oral options, international generics), losing access to compounded semaglutide would be a meaningful headwind. I assign maybe 25% probability to a worst-case scenario where compounded GLP-1s become unavailable and branded partnerships don't materialize, which would likely cut 2026 revenue growth from projected 30% to low double digits.

The second big risk is competition, and make no mistake, competition is intensifying.

Teladoc, Roman, Ro, and a dozen other telehealth platforms are all expanding into similar categories. Amazon launched RxPass, which offers generic medications for $5/month. CVS and Walgreens are building out digital health offerings. HIMS's competitive moat is their brand, user experience, and multi-specialty platform approach, but they're not operating in a vacuum. If someone replicates the model with better execution or deeper pockets, market share becomes contested.

Risk #3 is the international expansion, which could always disappoint. Replicating the U.S. playbook in markets with different regulatory environments, healthcare systems, and consumer behavior is hard. The ZAVA acquisition provides a beachhead in Europe, but proving product-market fit outside the U.S. will take time and capital. If international growth stalls, the path to $6.5 billion becomes materially harder.

The final risk on my radar is simply growth deceleration, which could always happen faster than expected. Subscriber growth already slowed from 38% year-over-year in Q1 2025 to 21% in Q3 2025. If that trend continues and they can't offset it with higher revenue per subscriber, the 2030 targets become unreachable.

I'm watching subscriber additions and retention metrics closely - any sign of sustained weakness would be enough to change my view.

As I mentioned, I have high conviction in the business model but acknowledgment of execution risk and volatility.

If HIMS hits their 2030 targets of $6.5 billion revenue and $1.3 billion EBITDA, the business will be generating approximately $325 million in quarterly EBITDA by then.

Apply a 15x EBITDA multiple - which is reasonable for a high-growth healthcare platform - and you get to a $19.5 billion valuation, or roughly 2.6x upside from today's $7.4 billion market cap. That's before any terminal value beyond 2030.

More conservatively, assume they only hit $5 billion revenue by 2030 with 15% EBITDA margins, generating $750 million annually. At 12x EBITDA (reflecting slower growth), that's a $9 billion valuation, still 20%+ upside from today.

I need to see evidence that subscriber growth sticks above 15% and revenue per subscriber continues expanding. The next critical data point comes with Q4 2025 earnings in February 2026.

The key metrics I'll track each quarter:

The next earnings report drops in late February 2026 for Q4 2025 results. I'll be listening for full-year 2026 guidance. If management projects $3+ billion in revenue with maintained margins, that confirms the growth trajectory toward 2030 targets remains intact.

When all is said and done, It’s an extremely compelling growth story, and I’m prepared to stomach the volatility unless the thesis breaks.

The Earnout Investor provides analysis and research but DOES NOT provide individual financial advice. Jamie Dejter may have a position in some of the stocks mentioned. All content is for informational purposes only. The Earnout Investor is not a registered investment, legal, or tax advisor, or a broker/dealer. Trading any asset involves risk and could result in significant capital losses. Please, do your own research before acquiring stocks.